Salidroside
Based on 46 publication(s) in Google Scholar
Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.
For research use only. We do not sell to patients.
- Purity: 99.88%
- CAS No.: 10338-51-9
- Formula: C14H20O7
- Molecular Weight:300.30
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Salidroside
More- Cell Metab. 2025 Apr 1;37(4):824-841.e8. [Abstract]
- Nat Commun. 2025 Jan 2;16(1):72. [Abstract]
- Chem Eng J. 1 May 2022, 135115.
- Phytomedicine. 2025 Nov 29:150:157633. [Abstract]
- Phytomedicine. 2024 Nov 9:135:156208. [Abstract]
- Phytomedicine. 2022 May:99:153964. [Abstract]
- Free Radic Biol Med. 2024 Mar:214:54-68. [Abstract]
- Phytother Res. 2024 Jun;38(6):2619-2640. [Abstract]
- Microchem J. 2026 Mar 6.
- Int J Oncol. 2019 Jun;54(6):1969-1980. [Abstract]
- Pharmaceuticals (Basel). 2026 Mar 16;19(3):487. [Abstract]
- Front Pharmacol. 2020 Nov 11;11:580407. [Abstract]
- Eur J Pharmacol. 2024 Apr 15:969:176459. [Abstract]
- Biosci Rep. 2023 Aug 31;43(8):BSR20230539. [Abstract]
- Int Immunopharmacol. 2023 Apr:117:109975. [Abstract]
- Invest Ophthalmol Vis Sci. 2021 Jul 1;62(9):25. [Abstract]
- Int Immunopharmacol. 2020 Apr;81:106243. [Abstract]
- Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2072-2082. [Abstract]
- J Dairy Sci. 2025 Sep;108(9):10136-10150. [Abstract]
- Mol Neurobiol. 2025 Nov 19;63(1):89. [Abstract]
- Front Cell Dev Biol. 2021 Nov 10;9:763864. [Abstract]
- iScience. 2026 Apr 4;29(5):115607. [Abstract]
- J Inflamm Res. 2025 Oct 27:18:14857-14869. [Abstract]
- Sci Rep. 2025 Jul 26;15(1):27294. [Abstract]
- Sci Rep. 2024 Mar 30;14(1):7548. [Abstract]
- Chem Res Toxicol. 2024 Jun 17;37(6):1053-1061. [Abstract]
- Cell Signal. 2025 May 15:111873. [Abstract]
- Mol Cell Biochem. 2025 May;480(5):3097-3116. [Abstract]
- Cardiovasc Toxicol. 2023 Dec;23(11-12):406-418. [Abstract]
- Heliyon. 2023 Oct 20;9(11):e21220. [Abstract]
- Toxicol Appl Pharmacol. 2026 Jun 23:514:117921. [Abstract]
- Eur J Med Res. 2024 Aug 17;29(1):423. [Abstract]
- Neurotox Res. 2026 Mar 19;44(2):12. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):4539-4558. [Abstract]
- Exp Eye Res. 2025 Apr 9:110386. [Abstract]
- Exp Eye Res. 2023 Feb:227:109350. [Abstract]
- Arch Physiol Biochem. 2024 Jun;130(3):257-274. [Abstract]
- Theriogenology. 2025 Jan 15:232:96-108. [Abstract]
- Exp Ther Med. 2023 Sep 14;26(5):507. [Abstract]
- Urolithiasis. 2026 Jan 2;54(1):25. [Abstract]
- Korean J Physiol Pharmacol. 2024 Nov 1;28(6):549-558. [Abstract]
- Curr Med Sci. 2025 Feb;45(1):104-113. [Abstract]
- Mol Cell Toxicol. 2026 Jan 20.
- Res Sq. 2024 May 22.
- Research Square Preprint. 2021 Sep.
- Oxid Med Cell Longev. 2020 Jul 23;2020:3549704. [Abstract]
-
Cell Imaging/Staining
-
Histological Imaging/Staining
-
Histological Imaging/Staining
-
Histological Imaging/Staining
-
IF
Biological Activity
|
mTOR |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
10.493 μM
Compound: Sal
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
|
[PMID: 34978808] |
| MDA-MB-231 | IC50 |
40 μM
Compound: 2
|
Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
|
[PMID: 33650861] |
| PC-12 | EC50 |
0.21 μM
Compound: Salidroside
|
Neuroprotective activity against CoCl2-induced neuronal injury in rat PC12 cells
Neuroprotective activity against CoCl2-induced neuronal injury in rat PC12 cells
|
[PMID: 31924497] |
| PC-12 | EC50 |
0.21 μM
Compound: Salidroside
|
Neuroprotective activity against CoCl2-induced neuronal injury in rat PC-12 cells assessed as increase in cell viability
Neuroprotective activity against CoCl2-induced neuronal injury in rat PC-12 cells assessed as increase in cell viability
|
[PMID: 32738992] |
| PC-12 | EC50 |
0.3 μM
Compound: Cpd i
|
Neuroprotective activity against CoCl2-induced cytotoxicity in rat PC12 cells assessed as increase in cell viability pretreated with CoCl2 for 8 hrs followed by incubation with drug and measured after 24 hrs by MTT assay
Neuroprotective activity against CoCl2-induced cytotoxicity in rat PC12 cells assessed as increase in cell viability pretreated with CoCl2 for 8 hrs followed by incubation with drug and measured after 24 hrs by MTT assay
|
[PMID: 33097301] |
Salidroside (100 μM) inhibits prolyl endopeptidase (PEP) activity (10.6±1.9%). Prolyl endopeptidase is an enzyme that plays a role in the metabolism of proline-containing neuropeptidase which is recognized to be involved in learning and memory[1].
Salidroside, one of the major phenylpropanoid glycosides found in R.?rosea L, is consumed almost daily as a nutritional supplement in many countries and has been identified possessing potential anti-fatigue and anoxia,anti-aging, and anti-Alzheimer's disease activities. Salidroside can improve muscle nutrition via increasing mTOR, p-mTOR, and MyHC expression[2].
SH-SY5Y cells are exposed to 0-600?μM MPP+ for 12-48?h and the results show that MPP+ results in a significant decrease of cell viability in a concentration and time-dependent manner. Cells are pretreated with 25-100?μM Salidroside (Sal) for 24?h and then exposed to 500?μM MPP+ for an additional 24?h. Salidroside concentration-dependently prevents MPP+-induced decrease of cell viability. Annexin V/PI staining is a common method for the detection of apoptotic cell. Salidroside significantly decreases the number of Annexin V/PI-stained cells treated by MPP+ which is in a concentration-dependent manner. Apoptotic cell could also be morphologically evaluated by Hoechst staining. In Hoechst staining, apoptotic cells are characterized by reduced nuclear size, chromatin condensation, intense fluorescence, and nuclear fragmentation. Salidroside notably inhibits MPP+-induced increase of chromatin condensation, intense fluorescence, and nuclear fragmentation in SH-SY5Y cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Salidroside can be used to induce testicular injury model in mice[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 10338-51-9
-
Appearance Solid
-
Molecular Weight 300.30
-
Formula C14H20O7
-
Color White to yellow
-
SMILES
O[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@@H]1OCCC2=CC=C(O)C=C2
-
Synonyms
Rhodioloside
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (46)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
2025 Apr 1;37(4):824-841.e8. PMID: 39879982 -
Nat Commun
Physiological premature aging of ovarian blood vessels leads to decline in fertility in middle-aged mice. [Abstract]2025 Jan 2;16(1):72. PMID: 39747922
Salidroside purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):72. [Abstract]
Live-cell imaging analysis tracking the growth of blood vessels of Tek-CreERT2;mTmG follicles from 12-month-old females with Sal (Salidroside, 50 μM), Ft1, Dosk or vehicle.
Salidroside purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):72. [Abstract]
Tip cells on growing follicles after 7 days of Sal (Salidroside, 300 mg/kg BW, once a day) or vehicle treatment (left), quantifying the number of tip cells (right) showing a significant increase in tip cells on growing follicles after 7 days of Sal treatment (n = 5).
Salidroside purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):72. [Abstract]
Intensity of Evans blue (arrowheads) in ovaries (left) of 12-month-old females after Sal (Salidroside, 300 mg/kg BW, once a day) or vehicle treatment. Quantification of the EB signal (right) indicating Sal treatment significantly increased the blood supply to the ovaries (n = 4).
Salidroside purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):72. [Abstract]
Ovarian morphology with or without Sal treatment (Salidroside, 300 mg/kg BW, once a day) at 12 months, exhibiting an increase in the number of growing follicles (arrows) in the Sal group compared to the control (n = 5 mice).
Salidroside purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):72. [Abstract]
Immunostaining detection of proliferating granulosa cells (red: BrdU, blue: Hoechst) in Sal (Salidroside, 300 mg/kg BW, once a day) and vehicle-treated ovaries at 12 months post-PMSG treatment. Statistical analysis revealing a significantly increase in GC proliferating ratio after Sal treatment compared to the control (n = 5).
-
-
Phytomedicine
Salidroside mitigates Oligoasthenospermia by attenuating ferroptosis via NF-κB pathway inhibition. [Abstract]2025 Nov 29:150:157633. PMID: 41351983 -
Phytomedicine
Salidroside facilitates neuroprotective effects in ischemic stroke by promoting axonal sprouting through promoting autophagy. [Abstract]2024 Nov 9:135:156208. PMID: 39550919 -
Phytomedicine
Salidroside inhibits doxorubicin-induced cardiomyopathy by modulating a ferroptosis-dependent pathway. [Abstract]2022 May:99:153964. PMID: 35180677 -
Free Radic Biol Med
BRG1 accelerates mesothelial cell senescence and peritoneal fibrosis by inhibiting mitophagy through repression of OXR1. [Abstract]2024 Mar:214:54-68. PMID: 38311259 -
Phytother Res
Salidroside directly activates HSC70, revealing a new role for HSC70 in BDNF signalling and neurogenesis after cerebral ischemia. [Abstract]2024 Jun;38(6):2619-2640. PMID: 38488455 -
-
Int J Oncol
Salidroside suppresses the growth and invasion of human osteosarcoma cell lines MG63 and U2OS in vitro by inhibiting the JAK2/STAT3 signaling pathway. [Abstract]2019 Jun;54(6):1969-1980. PMID: 31081055
Salidroside purchased from MedChemExpress. Usage Cited in: Int J Oncol. 2019 Jun;54(6):1969-1980. [Abstract]
Apoptosis‑related protein expression in MG63 cells in response to various concentrations of Salidroside is detected via western blot analysis.
-
Pharmaceuticals (Basel)
Salidroside Selectively Binds to SEC23A and Ameliorates Psychological Stress-Induced Hyperpigmentation. [Abstract]2026 Mar 16;19(3):487. PMID: 41901332 -
Front Pharmacol
CC-223, NSC781406, and BGT226 Exerts a Cytotoxic Effect Against Pancreatic Cancer Cells via mTOR Signaling. [Abstract]2020 Nov 11;11:580407. PMID: 33343350 -
Eur J Pharmacol
Tetrandrine alleviates pulmonary fibrosis by inhibiting alveolar epithelial cell senescence through PINK1/Parkin-mediated mitophagy. [Abstract]2024 Apr 15:969:176459. PMID: 38438063 -
Biosci Rep
Network pharmacology analysis combined with experimental validation to explore the therapeutic mechanism of salidroside on intestine ischemia reperfusion. [Abstract]2023 Aug 31;43(8):BSR20230539. PMID: 37530723 -
Int Immunopharmacol
Salidroside attenuates lipopolysaccharide-induced neuroinflammation and cognitive impairment in septic encephalopathy mice. [Abstract]2023 Apr:117:109975. PMID: 36948107 -
Invest Ophthalmol Vis Sci
Salidroside Prevents Hypoxia-Induced Human Retinal Microvascular Endothelial Cell Damage Via miR-138/ROBO4 Axis. [Abstract]2021 Jul 1;62(9):25. PMID: 34269814 -
Int Immunopharmacol
Salidroside suppresses group 2 innate lymphoid cell-mediated allergic airway inflammation by targeting IL-33/ST2 axis. [Abstract]2020 Apr;81:106243. PMID: 32070919 -
Invest Ophthalmol Vis Sci
Effects of Salidroside on Trabecular Meshwork Cell Extracellular Matrix Expression and Mouse Intraocular Pressure. [Abstract]2019 May 1;60(6):2072-2082. PMID: 31091314 -
J Dairy Sci
Salidroside protects bovine hepatocytes against fatty acid-induced lipid accumulation and inflammation by activating AMPK/SIRT1 pathway. [Abstract]2025 Sep;108(9):10136-10150. PMID: 40645487 -
Mol Neurobiol
Salidroside-Pretreated Small Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stem Cells Promote Blood-Spinal Cord Barrier Repair After Spinal Cord Injury in Mice. [Abstract]2025 Nov 19;63(1):89. PMID: 41261280 -
Front Cell Dev Biol
Curdione and Schisandrin C Synergistically Reverse Hepatic Fibrosis via Modulating the TGF-β Pathway and Inhibiting Oxidative Stress. [Abstract]2021 Nov 10;9:763864. PMID: 34858986 -
iScience
Natural senolytic activity of Rhodiola rosea extract alleviates age-associated phenotypes via paraptosis. [Abstract]2026 Apr 4;29(5):115607. PMID: 42028013 -
J Inflamm Res
Investigating the Role of Salidroside in Alleviating Acute Pancreatitis by Inhibiting the RIPK1/RIPK3/MLKL Pathway-Mediated Necroptosis in Pancreatic Acinar Cells in Rats. [Abstract]2025 Oct 27:18:14857-14869. PMID: 41181365 -
Sci Rep
2025 Jul 26;15(1):27294. PMID: 40715275 -
Sci Rep
Network pharmacology, computational biology integrated surface plasmon resonance technology reveals the mechanism of ellagic acid against rotavirus. [Abstract]2024 Mar 30;14(1):7548. PMID: 38555283 -
Chem Res Toxicol
Salidroside Inhibits α-Amanitin-Induced AML-12 Cell Apoptosis via the Regulation of PINK1/Parkin-Mediated Mitophagy and Mitochondrial Function. [Abstract]2024 Jun 17;37(6):1053-1061. PMID: 38847154 -
Cell Signal
METTL14 promotes TBK1 mRNA stability through IGF2BP3-recognized m6A modification and enhances mitophagy in BMSCs. [Abstract]2025 May 15:111873. PMID: 40381973 -
Mol Cell Biochem
Salidroside overcomes cisplatin resistance in ovarian cancer via the inhibition of CRNDE-mediated autophagy. [Abstract]2025 May;480(5):3097-3116. PMID: 39636431 -
Cardiovasc Toxicol
Salidroside Ameliorates Ischemia/Reperfusion-Induced Human Cardiomyocyte Injury by Inhibiting the Circ_0097682/miR-671-5p/USP46 Pathway. [Abstract]2023 Dec;23(11-12):406-418. PMID: 37740139 -
Heliyon
Salidroside attenuates atrial fibrosis and atrial fibrillation vulnerability induced by angiotensin-II through inhibition of LOXL2-TGF-β1-Smad2/3 pathway. [Abstract]2023 Oct 20;9(11):e21220. PMID: 37920527 -
Toxicol Appl Pharmacol
Salidroside suppresses hypoxia-induced ocular angiogenesis by modulating the acetylation of PFKFB3 protein in endothelial cells and regulating glycolytic activity. [Abstract]2026 Jun 23:514:117921. PMID: 42336299 -
Eur J Med Res
Salidroside enhances NO bioavailability and modulates arginine metabolism to alleviate pulmonary arterial hypertension. [Abstract]2024 Aug 17;29(1):423. PMID: 39152472 -
Neurotox Res
Tubuloside B Alleviates Aβ25-35 Induced PC12 Cell Injury by Attenuating Pyroptosis, Apoptosis and Excessive Autophagy. [Abstract]2026 Mar 19;44(2):12. PMID: 41854817 -
Naunyn Schmiedebergs Arch Pharmacol
Synthesizing network pharmacology, bioinformatics, and in vitro experimental verification to screen candidate targets of Salidroside for mitigating Alzheimer's disease. [Abstract]2025 Apr;398(4):4539-4558. PMID: 39503755 -
Exp Eye Res
A multi-omics study reveals molecular characteristics and therapeutic targets of salidroside in reducing TGF-β2-induced ECM expression. [Abstract]2025 Apr 9:110386. PMID: 40216062 -
Exp Eye Res
MicroRNA-210-3p mediates trabecular meshwork extracellular matrix accumulation and ocular hypertension - Implication for novel glaucoma therapy. [Abstract]2023 Feb:227:109350. PMID: 36566010 -
Arch Physiol Biochem
Salidroside inhibits insulin resistance and hepatic steatosis by downregulating miR-21 and subsequent activation of AMPK and upregulation of PPARα in the liver and muscles of high fat diet-fed rats. [Abstract]2024 Jun;130(3):257-274. PMID: 35061559 -
Theriogenology
2025 Jan 15:232:96-108. PMID: 39536623 -
Exp Ther Med
Salidroside inhibits renal ischemia/reperfusion injury‑induced ferroptosis by the PI3K/AKT signaling pathway. [Abstract]2023 Sep 14;26(5):507. PMID: 37822587 -
Urolithiasis
Salidroside attenuates calcium oxalate-induced renal injury via suppression of PANoptosis. [Abstract]2026 Jan 2;54(1):25. PMID: 41483174 -
Korean J Physiol Pharmacol
Salidroside attenuates sepsis-induced acute lung injury by inhibiting ferroptosis-dependent pathway. [Abstract]2024 Nov 1;28(6):549-558. PMID: 39467718 -
Curr Med Sci
Salidroside Enhances the Sensitivity of Lung Cancer Cells to Paclitaxel by Regulating the Wnt/β-catenin Signaling Pathway. [Abstract]2025 Feb;45(1):104-113. PMID: 40014194 -
-
-
-
Oxid Med Cell Longev
Salidroside Ameliorates Mitochondria-Dependent Neuronal Apoptosis after Spinal Cord Ischemia-Reperfusion Injury Partially through Inhibiting Oxidative Stress and Promoting Mitophagy. [Abstract]2020 Jul 23;2020:3549704. PMID: 32774670
Solvent & Solubility
H2O : 125 mg/mL (416.25 mM; Need ultrasonic)
DMSO : 100 mg/mL (333.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (16.65 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (16.65 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (333.00 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocol
SH-SY5Y cells are seeded in 96-well plates at 1×104 cells per well. After the treatment with Salidroside (25-100?μM) and MPP+, cell viability is measured by MTT assay. Briefly, cells are incubated with 500?μg/mL MTT at 37°C for 4?h. After that, the medium is removed and 150?μL DMSO is added and shaking is conducted for 10?min. Absorbance is measured at 570?nm in a microplate reader and the results are expressed as folds of control[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[4]
The 4-week-old male C57BL/6 mice are fed a high-fat diet (HFD) (n=16) or normal chow diet (n=8). After 10 weeks of the HFD, salidroside intervention (100 mg/kg/day) is initiated by gavage once a day for 5 weeks. The control groups are given vehicle (saline). The 4-week-old male C57Bl/KsJ (BKS) mice (wild type, n=8) and BKS.Cg-Dock7m +/+ Leprdb/J (db/db) mice (n=16) are used. Salidroside (100 mg/kg/day) is administrated orally by gavage once a day for 5 weeks. The control groups are given vehicle (saline). Fasting blood glucose and body weight of mice are monitored every 5 days. Glucose measurements are performed on blood drawn from the tail vein using a Glucometer.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Fan W, et al. Prolyl endopeptidase inhibitors from the underground part of Rhodiola sachalinensis. Chem Pharm Bull (Tokyo). 2001 Apr;49(4):396-401. [Content Brief]
[2]. Ju L, et al. Salidroside, A Natural Antioxidant, Improves β-Cell Survival and Function via Activating AMPK Pathway. Front Pharmacol. 2017 Oct 18;8:749. [Content Brief]
[3]. Chen X, et al. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activatingmTOR signalling. J Cachexia Sarcopenia Muscle. 2016 May;7(2):225-32. [Content Brief]
[4]. Wu L, et al. Salidroside Protects against MPP+-Induced Neuronal Injury through DJ-1-Nrf2 Antioxidant Pathway. Evid Based Complement Alternat Med. 2017;2017:5398542. [Content Brief]
[5]. Li R, et al. Salidroside Protects Dopaminergic Neurons by Enhancing PINK1/Parkin-Mediated Mitophagy. Oxid Med Cell Longev. 2019 Sep 10;2019:9341018. [Content Brief]
[6]. Wang Z, et al. Salidroside Ameliorates Furan-Induced Testicular Inflammation in Relation to the Gut-Testis Axis and Intestinal Apoptosis. J Agric Food Chem. 2023 Nov 9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 3.3300 mL | 16.6500 mL | 33.3000 mL | 83.2501 mL |
| 5 mM | 0.6660 mL | 3.3300 mL | 6.6600 mL | 16.6500 mL | |
| 10 mM | 0.3330 mL | 1.6650 mL | 3.3300 mL | 8.3250 mL | |
| 15 mM | 0.2220 mL | 1.1100 mL | 2.2200 mL | 5.5500 mL | |
| 20 mM | 0.1665 mL | 0.8325 mL | 1.6650 mL | 4.1625 mL | |
| 25 mM | 0.1332 mL | 0.6660 mL | 1.3320 mL | 3.3300 mL | |
| 30 mM | 0.1110 mL | 0.5550 mL | 1.1100 mL | 2.7750 mL | |
| 40 mM | 0.0833 mL | 0.4163 mL | 0.8325 mL | 2.0813 mL | |
| 50 mM | 0.0666 mL | 0.3330 mL | 0.6660 mL | 1.6650 mL | |
| 60 mM | 0.0555 mL | 0.2775 mL | 0.5550 mL | 1.3875 mL | |
| 80 mM | 0.0416 mL | 0.2081 mL | 0.4163 mL | 1.0406 mL | |
| 100 mM | 0.0333 mL | 0.1665 mL | 0.3330 mL | 0.8325 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.